

REFERENCES

1. **Ahmad, N. and Mukhtar, H. (1999):**Green tea polyphenols and cancer: biologic mechanisms and practical implications. *Nutr. Rev.* 57:78–83.
2. **Akinyanju, P. and Yudkin, J. (1967):** Effect of coffee and tea on serum lipids in rats. *Nature.* 214:426-427.
3. **Alessio, H. M.; Hagerman, A. E.; Romanello, M.; Carando, S.; Threlkeld, A. E.; et al. (2003):** Consumption of green tea protects rats from exercise-induced oxidative stress in kidney and liver. *Nutr. Res.* 22: 1177–1188.
4. **Alschuler, L. (1998):** Green Tea: Healing tonic. *Am. J. Natur. Med.* 5:28-31
5. **Álvarez, E.; Campos-Toimil, M.; Orallo, F. (2004):** Epigallocatechin-3-gallate induces contraction of the rat aorta by a calcium influx-dependent mechanism. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 369 : 496–506.
6. **Álvarez, E.; Campos-Toimil, M.; Justiniano-Basaran, H.; Lugnier, C.; Orallo, F. (2006):**Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. *British Journal of Pharmacology.* 147, 269–280.
7. **Andrews, TC.; Ballantyne, C.,; Hsia, JA Kramer, JH. (2001):**Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. *Am. J. Med.* 111(3):185-91.

8. **Armstrong, E. J.; Safo, P.K.; et al. (2005):** Pharmacology of Cholesterol and Lipoprotein Metabolism. Eds: Golan DE., et al. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. pgs: 389-69. Baltimore, Lippincott Williams & Wilkins.
9. **Bakker-Arkema, RG.; Best, J.; Fayyad, R.; Heinonen, TM.; Marais, AD.; Nawrocki, JW.; Black, DM. (1997):** A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis. 131(1):17-23.
10. **Balz, F. and Jane, V. (2003):** Antioxidant Activity of Tea Polyphenols In Vivo: Evidence from Animal Studies. Nutr. 133: 3275S–3284S.
11. **Bayorh MA, Mann G, Walton M, Eatman D. (2006):** Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats. Clin Exp Hypertens. 28(2):121-32.
12. **Berger, ME.; Golub, MS.; Chang, CT.; Al-Kharouf, JA.; Nyby, MD.; Hori, M.; Brickman, AS.; Tuck, ML. (1992):** Flavonoid potentiation of contractile responses in rat blood vessels. J. Pharmacol. Exp. Ther. 263:78–83
13. **Bhatnagar, D. (1998):** Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol. Ther. 79: 205-3.
14. **Black, H.R. (1999):** Optimal blood pressure: How should we go ? Am. J. Hypertens. 12: 113S -120S.
15. **Bloth, K. (1954):** Biological synthesis of cholesterol. In: The Harvey Lectures ; v 48. New York: Academic Press; 1954. p 68-88.

16. **Bloth, K. (1965):** The biological synthesis of cholesterol. *Science*. 150: 19-28.
17. **Boyd, H.C.; Gown, A.M.; Wolfbaur, G.; Chait, A. (1989):** Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions. *Am. J. Pathol.*; 135,815-825.
18. **Brent, R.L.; Beckman, D.A. (1991):** Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counselors. *Teratology*. 43(6):543 6.
19. **Brown, C.A.; Bolton-Smith, C.; Woodward, M.; Tunstall-Pedoe, H. (1993):** Coffee and tea consumption and the prevalence of coronary heart disease in men and women: results from the Scottish Heart Health Study. *J. Epidemiol. Community Health* 47: 171–175.
20. **Brown, J.E.; Khodr, H.; Hider, R.C.; Rice-Evans, C.A. (1998):** Structural dependence of flavonoid interactions with Cu^{2+} ions: implications for their antioxidant properties. *Biochem. J.* 330: 1173–1178.
21. **Bu-Abbas, A.; Clifford, M.N.; Ioannides, C.; Walker, R. (1995):** Stimulation of rat hepatic UDP-glucuronosyl transferase activity following treatment with green tea. *Food Chem. Toxicol.* 33: 27–30.

22. **Burn, J.H. (1952):** Practical pharmacology. Blackwell Scientific Publications; P35-37.
23. **Bursill, C.; Roach, PD.; Bottema, CD.; Pal, S. (2001):** Green tea up-regulates LDL receptor through the sterol-regulated element binding protein in HepG2 liver cells. J. Agric. Food Chem. 49:5639-5645.
24. **Caggiula, AW. and Mustad, VA. (1997):** Effects of dietary fat and fatty acids on coronary artery disease risk and total and lipoprotein cholesterol concentrations: epidemiology studies. Am. J. Clin. Nutr. 65:1597S– 1610S.
25. **Cai, Y.; Anavy, N.D.; Chow, H.H. (2002):** Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats. Drug Metab. Dispos. 30(11):1246-9.
26. **Canjano, J.L.; Carmen, R.S.; Manuel, M.M. (1979):** Effect of antihypertensive treatment on systolic blood pressure and renin in Experimental hypertension in rats. J. Pharmacol. Exp. Ther. 208(2):310-3.
27. **Cao, J.; Xu, Y.; Chen, J.; Klaunig, J.E. (1996):** Chemopreventive effects of green and black tea on pulmonary and hepatic carcinogenesis. Fundam. Appl. Toxicol. 29: 244–250.
28. **Chan, PT.; Fong, WP.; Cheung, YL.; Ho, WK.; Chen, ZY. (1999):** Jasmine green tea epicatechins are hypolipidemic in hamsters fed a high fat diet. J. Nutr. 129:1049-1101.

-
29. **Chan, M.M.; Fong, D.; Ho, C.T.; Huang, H.I. (1997):** Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. *Biochem. Pharmacol.* 54: 1281–1286.
30. **Chanadiri, T.; Sanikidze, T.; Esaishvili, M.p; Chkhikvishvili, I.; Datunashvili, I. (2005):** Effectiveness of green tea catechines for the correction of the alimentary obesity in the experiment. *Georgian Med. News.* 9: 61-3.
31. **Chantre, P.; Lairon, D. (2002):** Recent findings of green tea extract (AR25; Exolise) and its activity for the treatment of obesity. *Phytomedicine.* 9: 3–8.
32. **Chen, C.; Yu, R.; Owuor, E.D.; Kong, A.N. (2000):** Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. *Arch. Pharm. Res.* 23: 605–612.
33. **Chen, L.; Lee, M.J.; Yang, C.S. (1997):** Absorption, distribution and elimination of tea polyphenols in rats. *Drug Metab. Dispos.* 25: 1045–1050.
34. **Chen, X.; Li, N.; Liao, J.; Yang, G.; Wang, S.; Josephson, Y.; Han, C.; Chen, J.; Huang, M.T.; Yang, C.S. (2002):** Inhibition of 7,12-dimethylbenz[a] anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. *Carcinogenesis* 23: 1307–1313.

-
35. **Chen, Z.Y.; Law, W.I.; Yao, X.Q.; Lau, C.W.; Ho, W.K.; Huang, Y. (2000):**Inhibitory effects of purified green tea epicatechins on contraction and proliferation of arterial smooth muscle cells. *Acta. Pharmacol. Sin.* 21, 835–840.
36. **Chyu, K.; Babbidge, S.M.; Zhao, X.; Dandillaya, R.; et al. (2004):** Differential Effects of Green Tea–Derived Catechin on Developing Versus Established Atherosclerosis in Apolipoprotein E- Null Mice. *Circulation.* 109:2448-2453.
37. **Cohn, J.N.; Johnson, G.; Ziesche, S.; Cobb, F.; Francis, G.; Tristani, F. (1991):** A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N. Engl. J. Med.* 325:303-310.
38. **Crespy, V. and Williamson, G. (2004):**A Review of the Health Effects of Green Tea Catechins in In Vivo Animal Models *J. Nutr.* 134: 3431S–3440S.
39. **Davie, A.P.; Dargie, H.J.; Nai, S.; McMurry, J.J.V. (1999):**Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. *Circulation.* 100:268-273.
40. **David, J.; Guo, P.; Nai, S.; Zong, G.; et al. (2003):**Cholesterol-lowering effect of a theaflavin-enriched green tea extract. *Arch. Intern. Med.* 163:1448-1453.
41. **DerMarderosian, A. (1999):** The Review of Natural Products. St. Louis, MO: Facts and Comparisons, Wolters Kluwer Co.

-
42. **Desager, J.P.; Hormans, Y. (1996):** Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31:348-371.
43. **Dietschy, J.M. (1997):** Theoretical considerations of what regulation low-density- lipoprotein and high-density-lipoprotein cholesterol. Am. J. Clin. Nutr. 65:1581S–1589S.
44. **DiPette, D.J.; Ferraro, J.C.; Evans, R.R.; Martin, M. (1985):** Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin. Pharmacol. Ther. 38(2):199-204.
45. **Donovan, J. L.; Crespy, V.; Manach, C.; Morand, C.; Besson, C.; Scalbert, A.; Remesy, C. (2001):** Catechin is metabolized by both the small intestine and liver of rats. J. Nutr. 131: 1753–1757.
46. **Dulloo, A.; Duret, C.; Rohrer, D.; Girardier, L.; Mensi, N.; Fathi, M.; Chantre, P.; Vandermander, J. (1999):** Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am. J. Clin. Nutr. 70:1040–1045,
47. **Dulloo, AG.; Seydoux, J.; Girardier, L.; et al. (2000):** Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine, and sympathetic activity. Int. J. Obes. Relat. Metab. Disord. 24:252-258.
48. **Dury, R.A.B. and Wallington, E.A. (1967):** Carleton Histological Technique, 4th ed. Oxford University Press, Oxford, P. 129.

49. **Dwyer, J. (1995):** Overview: dietary approaches for reducing cardiovascular disease risks. *J. Nutr.* 125:656–665.
50. **Embola, C.W.; Weisburger, J.H.; Weisburger, M.C. (2001):** Urinary excretion of N-OH-2-amino-3-methylimidazo[4,5-f]quinoline-N-glucuronide in F344 rats is enhanced by green tea. *Carcinogenesis*. 22: 1095–1098.
51. **Fitzpatrick, D.F.; Hirschfield, S.L.; Ricci, T.; Jantzen, P.; Coffey, R.G. (1995):** Endothelium dependent vasorelaxation caused by various plant extracts. *J. Cardiovasc. Pharmacol.* 26:90-95.
52. **Frayling, T.M.; Timpson, N.J.; Weedon, M.N. (2007):** "A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity". *Science*. 316 (5826): 889-94
53. **Frederickson, D.S. and Lee, R.S. (1965):** A system for phenotyping hyperlipidemia. *Circulation*. 31:321-7.
54. **Frick, M.H.; Elo, O.; Haapa, K.; Heinonen, O.P.; Heinsalmi, P.; Helo P. (1987):** Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors , and incidence of coronary heart disease. *N. Engl. J. Med.* 317: 1237-45.
55. **Frolich, J.C.; Hollifield, J.W.; Michelakis, A.M.; Vesper, B.S.; Wilson, J.P.; et al. (1989):** Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects: independence of sodium retention. *Circ. Res.* 44:781-787.

56. **Fujita, K.; Matsumura, Y.; Kita, S.; Miyazaki, Y.; Hisaki, K.; Takaoka, M.; Morimoto, S. (1995):** Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. *Br. J. Pharmacol.* 114(5):925-30.
57. **Furchgott, R.F. and Bhadrakom, S. (1953):** Reactions of strips of rabbit aorta to epinephrine, isoproterenol, sodium nitrite and other drugs. *J. Pharmacol. Exp. Ther.* 142 : 39 – 58.
58. **Gardner, C.D.; Chatterjee, L.M.; Carlson, J.J. (2001):** The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. *Atherosclerosis.* 154: 213-20.
59. **Ghasi, S.; Nwobodo, E.; Ofili, J.O. (2000):** Hypocholesterolemic effects of crude extract of leaf of *Moringa oleifera* Lam in high-fat diet fed Wistar rats. *J. Ethnopharmacol.* 69: 21-5.
60. **Gibbons, G.F.; Mitropoulos, K.A.; Myant, N.B. (1982):** *Biochemistry of cholesterol.* Amsterdam: Elsevier. p 369.
61. **Graham, H.N. (1992):** Green tea composition, consumption, and polyphenol chemistry. *Prev. Med.* 21:334-350.
62. **Grassi, G.; Colombo, M.; Seravalle, G.; Spaziani, D.; Mancia, G. (1998):** Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. *Hypertension.* 31 : 64 – 67.
63. **Green, M.S. and Jucha, E. (1986):** Association of serum lipids with coffee, tea, and egg consumption in free living subjects. *J. Epidemiol. Community Health.* 40:324-329.

-
64. **Guazzi, M.D.; Campodonico, J.; Celeste, F.; Guazzi, M.; et al. (1998):** Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin. Pharmacol. Ther. 63(1):79-86.
65. **Guo, Q.; Zhao, B.; Shen, S.; Hou, J.; Hu, J.; Xin, W. (1999):** ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers. Biochim. Biophys. Acta. 1427: 13–23.
66. **Gupta, R.S.; Kumar, P.; Sharma, A.; Bharadwaj, T.N.; Dixit, V.P. (2000):** Hypocholesterolemic activity of *Marsilea minuta* in gerbils. Fitoterapia. 71: 113-7.
67. **Haenen, G.R.; Paquay, J.B.; Korthouwer, R.E.; Bast, A. (1997):** Peroxynitrite scavenging by flavonoids. Biochem. Biophys. Res. Commun. 236: 591–593.
68. **Hall, J.E.; Guyton, A.C.; Smith, M.J.; Coleman, T.G. (1980):** Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am. J. Physiol., 239:F271-F280.
69. **Hao, J.; Kim, C.H.; Tae-Sun Ha, T.S.; Ahn, H.Y. (2007):** Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J. Vet. Sci. 8(2), 121–129.
70. **Hasegawa, N.; Yamada, N.; Mori, M. (2003):** Powdered green tea has antilipogenic effect on Zucker rats fed a high-fat diet. Phytother. Res. 17: 477– 480.

-
71. **Hasegawa, R.; Chujo, T.; Sai-Kato, K.; Umemura, T.; Tanimura, A.; Kurokawa, Y. (1995):** Preventive effects of green tea against liver oxidative DNA damage and hepatotoxicity in rats treated with 2-nitropropane. *Food Chem. Toxicol.* 33: 961–970.
72. **Hill, B.A. (1971):** Principles of medical statistics 9th ed. London: limited publication, 147-283.
73. **Himeno, E.; Nishino, K.; Nakashima, Y. (1996):** Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. *Am. Heart. J.* 131:313.
74. **Hirose, M.; Hasegawa, R.; Kimura, J.; Akagi, K.; Yoshida, Y.; et al. (1995):** Inhibitory effects of 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), green tea catechins and other antioxidants on 2-amino-6-methyldipyrido [1,2-a:3,2-d]imidazole (Glu-P-1)-induced rat hepatocarcinogenesis and dose-dependent inhibition by HTHQ of lesion induction by Glu-P-1 or 2-amino-3,8-dimethylimidazo [4,5-f] quinoxaline (MeIQx) Carcinogenesis. 16: 3049–3055.
75. **Hirose, M.; Mizoguchi, Y.; Yaono, M.; Tanaka, H.; Yamaguchi, T.; Shirai, T. (1997):** Effects of green tea catechins on the progression or late promotion stage of mammary gland carcinogenesis in female Sprague-Dawley rats pretreated with 7,12-dimethylbenz(a)anthracene. *Cancer Lett.* 112: 141–147.
76. **Hodgson, J.; Puddey, I.; Burke, V.; Beilin, L.; Jordan, N. (1999):** Effects on blood pressure of drinking green and black tea. *J. Hypertension* 17:457–463.

-
77. **Hoelscher, D.D.; Weir, M.R.; Bakris, G.L. (1995):**Hypertension in diabetic patients: an update of interventional studies to preserve renal function. *J. Clin. Pharmacol.* 35(1):73-80.
78. **Holmgren, P.R. and Brown, A.C. (1993):**Serum cholesterol levels of nondiabetic and streptozotocin diabetic rats fed a high cholesterol diet. *Artery* 20:337–345.
79. **Hotta, Y.; Huang, L.; Muto, T.; Yajima, M.; Miyazeki, K.; et al. (2006):**Positive inotropic effect of purified green tea catechin derivative in guinea pig hearts: the measurements of cellular Ca²⁺ and nitric oxide release. *Eur. J. Pharmacol.* 15;552(1-3):123-130.
80. **Hozumi, T.; Yoshida, M.; Ishida, Y.; Mimoto, H.; Sawa, J.; Doi, K.; Kazumi, T. (1995):**Long term effects of dietary fiber supplementation on serum glucose and lipoprotein levels in diabetic rats fed a high cholesterol diet. *Endocrinol. J.* 42:187–192.
81. **Huang, Y.; Zhang, A.; Lau, C.W.; Chen, Z.Y. (1998):**Vasorelaxant effects of purified green tea epicatechin derivatives in rat mesenteric artery. *Life Sci.* 63, 275–283.
82. **Ikada, I.; Imasato, Y.; Sasaki, E.; et al. (1992):**Tea catechins decrease micellar solubility and intestinal absorption of cholesterol in rats. *Biochim. Biophys. Acta.* 1127:141-146.
83. **Imai, K. and Nakachi, K. (1995):** Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. *BMJ.* 310:693-696.

- 84. Imai, K.; Suga, K.; Nakachi, K. (1997):**Cancer-preventative effects of drinking tea among a Japanese population. *Prev. Med.* 26:769-775.
- 85. Inoue, T. and Node, K. (2007):** Statin Therapy for Vascular Failure. *Cardiovasc. Drugs Ther.* 17682928.
- 86. Israili, Z.H. and Hall, W.D. (1992):**Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. *Ann. Intern. Med.* 1;117(3):234-42.
- 87. Jackson, E.K. (2001):**Renin and Angiotensin in: Goodman & Gilmans: The Pharmacological Basis of Therapeutics, 10th ed., P.823. Joel G. Hardman & Lee E. Limbird (editors). McGraw-Hill, Medical Publishing Division.
- 88. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (2003):** The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch. Intern. Med.* 42;1206-1252;
- 89. Juhel, C.; Armand, M.; Pafumi, Y.; et al. (2000):** Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. *J. Nutr. Biochem.* 11:45-51.
- 90. Kaplan, N.M. (1994):** Treatment of hypertension. Drug therapy: In Kaplan NM. *Clinical Hypertension*. 6th ed. Baltimore Med: Williams & Wilkins; 191 – 280.

91. **Kaplan, N.M. (2001):** Systemic hypertension : mechanism and diagnosis. In Heart Disease. A text book of cardiovascular medicine, Brounwald, E.; Zipes, D.P. and Libby, P. (Eds), 6th ed., Saunder Compnay, Philadelphia. PP. 941 – 971.
92. **Katzman, M.A.; Jacobs, L.; Marcus, M.; Vermani, M.; Logan, A.C. (2007):**Weight gain and psychiatric treatment: is there as role for green tea and conjugated linoleic acid? Lipids in Health and Disease, 6:14.
93. **Kavanagh, K.T.; Hafer, L.J.; Kim, D.W.; Mann, K.K.; Sherr, D.H.; Rogers, A.E.; Sonenshein, G.E. (2001):** Green tea extracts decrease carcinogen- induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J. Cell Biochem. 82: 387–398.
94. **Keilani, T.; Schlueter, W.; Batlle, D. (1995):**Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J. Clin. Pharmacol. 35(1):87-97.
95. **Khan, S.G.; Katiyar, S.K.; Agarwal, R.; Mukhtar, H. (1992):**Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res. 52: 4050–4052.
96. **Klatsky, A.L.; Petitti, D.B.; Armstrong, M.A.; Friedman, G.D. (1985):** Coffee, tea and cholesterol. Am. J. Cardiol. 55:577–578.

97. **Kleemann, R. and Kooistra, T. (2005):** HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol Current Drug Targets. Cardiovascular & Haematological Disorders. 5, 441-453.
98. **Kono, S.; Shinchi, K.; Ikeda, N.; Yanai, F.; Imanishi, K. (1992):** Green tea consumption and serum lipids: a cross sectional study in northern Kyushu, Japan. Prev. Med. 21:526-531.
99. **Lahera , V.; Goicoechea , M.; Vinuesa , S.G.; Miana, M.; et al. (2007):**Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007 ;14 (2):243-8 17266583.
100. **Laver, M.S.; Anderson, K.M.; Kangel, W.B.; Levy, D. (1991):** The impact of obesity on left ventricular mass and geometry. JAMA. 266:231.
101. **Lee, M.J.; Maliakal, P.; Chen, L.; XMeng, X.; Bondoc, F.Y.; et al. (2002):** Pharmacokinetics of Tea Catechins after Ingestion of Green Tea and Epigallocatechin-3-gallate by Human. Cancer Epidemiology Biomarkers & Prevention. 11; 1025-1032.
102. **Li, N.; Han, C.; Chen, J. (1999):**Tea preparations protect against DMBA-induced oral carcinogenesis in hamsters. Nutr. Cancer. 35: 73–79.
103. **Lilja, J.J.; Kivisto, K.T.; Neuvonen, P.J. (1999):**Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66:118-127.

-
- 104. Lin, B.H.; Guthrie, J.; Frazao, E. (1999):** "Nutrient contribution of food away from home". In: Frazao E (Ed). America's Eating Habits: Changes and Consequences. Agriculture Information Bulletin No. 750, US Department of Agriculture, Economic Research Service, Washington, DC, pp. 213–239.
- 105. Lin, Y.L. and Lin, J.K. (1997):** Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. *Mol. Pharmacol.* 52: 465– 472.
- 106. Lin, Y.S.; Tsai, Y.J.; Tsay, J.S.; Lin, J.K. (2003):** Factors affecting the levels of tea polyphenols and caffeine in tea leaves. *J. Agric. Food Chem.* 26;51(7):1864-73.
- 107. Lipman, T.H.; Hayman, L.L.; Fabian, C.V.; DiFazio, D.A.; Hale, P.M.; Goldsmith, B.M. (2000):** Risk factors for cardiovascular disease in children with type I diabetes. *Nurs. Res.* 49(3):160-166.
- 108. Little, J.A.; Shanoff, H.M.; Cisma, A.; Yano, R. (1966):** Coffee and serum lipids in coronary heart disease. *Lancet.* 1:732-434.
- 109. Loest, H.B.; Noh, S.K.; Koo, S.I. (2002):** Green tea extract inhibits the lymphatic absorption of cholesterol and alpha-tocopherol in ovariectomized rats. *J. Nutr.* 132: 1282–1288.
- 110. Lorenz, M.; Wessler, S.; Follmann, E.; Michaelis, W.; Dusterhoft, T.; baumann, G.; Stangl, K.; Stangl, V. (2004):** A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Aktdependent pathway and leads

- to endothelial-dependent vasorelaxation. *J. Biol. Chem.* 279, 6190–6195.
- 111. Macgregor; Shaw, J.; Valente (1995):** Non pharmacological treatment of hypertension. *Am. J. Hypertension*; 10(25): 60 – 80.
- 112. Magnus, (1904):** *Pflugers Arch. Ges. Physiol.* 102, 123. quoted from pharmacological experiments on Isolated preparations, 1970 by the staff of department of pharmacology, University of Edinburgh. Ess. Livingstone, Edinburgh, London
- 113. Maliakal, P.P.; Coville, P.F.; Wanwimolruk, S. (2001):** Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats. *J. Pharm. Pharmacol.* 53: 569–577.
- 114. Malinowski, J.M. (1998):** Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor. *Am. J. Health-Syst. Pharm.* 55:2253 2267.
- 115. Masatsune, S.; Hirotoshi, K.; Akimitsu, T.; Hitoshi, S.; Kaoruko, T.; Tomotaka, Y.; Rumi, K.; Nobuhiro, Y. (2005):** Effects of Atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. *J Atheroscler. Thromb.* 12: 77-84.
- 116. Materson, B.J. (1992):** Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. *Am. J. Cardiol.* 69(10):46C-53C.
- 117. Matsumoto, N.; Okushio, K.; Hara, Y. (1998):** Effect of black tea polyphenols on plasma lipids in cholesterol-fed rats. *J. Nutr. Sci. Vitaminol.* 44:337-342.

-
118. **McGarry, J.D. (1998):**Glucose-fatty acid interactions in health and disease. *Am. J. Clin. Nutr.* 67:500S–504S.
119. **Mei, Z.; Grummer-Strawn, L.M.; Pietrobelli, A.; Goulding, A.; Goran, M.I.; Dietz, W.H. (2002):**Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. *Am. J. Clin. Nutr.* 75:978-85
120. **Mira, L.; Fernandez, M.T.; Santos, M.; Rocha, R.; Florencio, M.H.; Jennings, K.R. (2002):**Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. *Free Radic. Res.* 36: 1199–1208.
121. **Miura, S.; Watanabe, J.; Sano, M.; Tomita, T.; Tomita, I. (1994):**The inhibitory effects of tea polyphenols (flavan-3-ol derivatives) on Cu²⁺-mediated oxidative modification of low density lipoprotein. *Biol. Pharm. Bull.* 17: 1567–1572.
122. **Miura, S.; Watanabe, J.; Sano, M.; Tomita, T.; Tomita, I.; Osawa, T.; Hara, Y. (1995):** Effects of various natural antioxidants on the Cu²⁺ mediated oxidative modification of low density lipoprotein. *Biol. Pharm. Bull.* 18: 1–4.
123. **Miura, Y.; Chiba, T.; Miura, S.; Tomita, I.; Umegaki, K.; Ikeda, M.; Tomita, T. (2000):**Green tea polyphenols (flavan 3-ols) prevent oxidative modification of low density lipoproteins: an ex vivo study in humans. *J. Nutr. Biochem.* 11: 216–222.

-
124. **Miura, Y.; Chiba, T.; Tomita, I.; Koizumi, H.; Miura, S.; Umegaki, K.; Hara, Y.; Ikeda, M.; Tomita, T. (2001):** Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. *J. Nutr.* 131: 27–32.
125. **Modan, M.; Almog, S.; Fuchs, Z.; Chetrit, A.; Lusky, A.; Halkin, H. (1991):** Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. *Hypertension.* 17(4):565-73.
126. **Muramatsu, K.; Fukuyo, M.; Hara, Y. (1986):** Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. *J. Nutr. Sci. Vitaminol.* 32:613-622.
127. **Murase, T.; Nagasawa, A.; Suzuki, J.; Hase, T.; Tokimitsu, I. (2002):** Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. *Int. J. Obes. Relat. Metab. Disord.* 26: 1459–1464.
128. **Nakachi, K.; Matsuyama, S.; Miyake, S.; Suganuma, M.; Imai, K. (2000):** Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. *Biofactors.* 13:49–54,.
129. **Nakagawa, T. and Yokozawa, T. (2002):** Direct scavenging of nitric oxide and superoxide by green tea. *Food Chem. Toxicol.* 40: 1745–1750.
130. **Nanjo, F.; Honda, M.; Okushio, K.; Matsumoto, N.; Ishigaki, F.; Ishigami, T.; Hara, Y. (1993):** Effects of dietary tea catechins on alpha-tocopherol levels, lipid peroxidation, and erythrocyte deformability in rats fed on high palm oil and perilla oil diets. *Biol. Pharm. Bull.* 16: 1156–1159.

- 131. National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP, 2002):** Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report. *Circulation*. 17;106(25):3143-3421
- 132. National Institute of Health and Clinical Excellence (NICE, 2006):** Clinical Guideline 43 (CG43): "Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children".
- 133. National Institutes of Health (NIH, 2000):** Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: "The Evidence Report". NHLBI document 98-4083.
- 134. Negishi, H.; Xu, J.W.; Ikeda, K.; Njelekela, M.; Nara, Y.; Yamori, Y. (2004):** Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. *J. Nutr.* 134: 38–42.
- 135. Nelson, M. and Poulter, J. (2004):** Impact of tea drinking on iron status in the UK: a review. *J. Hum. Nutr. Diet.* 17: 43–54.
- 136. Noma, A.; Okabe, H.; Nakayama, K.; Ueno, Y.; Shinohara, H. (1979):** Improved method for simultaneous determination of cholesterol in high- and low-density lipoproteins. *Clin. Chem.* 25:1480-1481.
- 137. Oberman, A.; Wassertheil-Smoller, S.; Langford, H.G. (1990):** Pharmacological and nutritional treatment of mild hypertension. *Ann. Intern. Med.* 112:89.

-
138. **Okushio, K.; Suzuki, M.; Matsumoto, N.; Nanjo, F.; Hara, Y. (1999):** Methylation of tea catechins by rat liver homogenates. *Biosci. Biotechnol. Biochem.* 63: 430–432.
139. **Ostlund, R.E.; Staten, M.; Kohrt, W.M.; Schultz, J.; Malley, M. (1990):** The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. *N. Engl. J. Med.* 322(4):229-34.
140. **Paquay, J.B.; Haenen, G.R.; Stender, G.; Wiseman, S.A.; Tijburg, L.B.; Bast, A. (2000):** Protection against nitric oxide toxicity by tea. *J. Agric. Food Chem.* 48: 5768–5772.
141. **Pfeffer, M.A.; Braunwald, E.; Moye, L.A.; Basta, L.; Brown, E.J.; et al. (1995):** Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. *N. Engl. J. Med.* 327: 669-677.
142. **Princen, H.; Duyvenvoorde, W.; Buytenhek, R.; Blonk, C.; Tijburg, L.; et al. (2007):** No Effect of Consumption of Green and Black Tea on Plasma Lipid and Antioxidant Levels and on LDL Oxidation in Smokers. *Arterioscler. Thromb. Vasc. Biol.* 18:833-841.
143. **Raederstorff, D.G.; Schlachter, M.F.; Elste, V.; Weber, P. (2003):** Effect of EGCG on lipid absorption and plasma lipid levels in rats. *J. Nutr. Biochem.* 14: 326–332.
144. **Record, I.R.; McInerney, J.K.; Dreosti, I.E. (1996):** Black tea, green tea, and tea polyphenols. Effects on trace element status in weanling rats. *Biol. Trace Elem. Res.* 53: 27–43.

-
145. **Reid, J.L.; Ziven, J.A.; Kapin, I.J. (1975):** Central and peripheral adrenergic mech. In the devlopment of essential hypertension in rats. Clin. Res. 37; 569 – 76.
146. **Reisin, E.; Frohlich, E.D.; Messerli, F.H.; Dreslinski, G.R.; Dunn, F.G.; Jones, M.M.; Batson, H.M. (1983):** Cardiovascular changes after weight reduction in obesity hypertension. Ann. Intern. Med. 98(3):315-9.
147. **Rhee, S.J.; Choi, J.H.; Park, M.R. (2002):**Green tea catechin improves microsomal phospholipase A2 activity and the arachidonic acid cascade system in the kidney of diabetic rats. Asia Pac. J. Clin. Nutr. 11: 226–231.
148. **Rhee, S.J.; Kim, M.J.; Kwag, O.G. (2002):**Effects of green tea catechin on prostaglandin synthesis of renal glomerular and renal dysfunction in streptozotocin-induced diabetic rats. Asia Pac. J. Clin. Nutr. 11: 232–236.
149. **Rice-Evans, C.A.; Miller, N.J.; Bolwell, P.G.; Bramley, P.M.; Pridham, J.B. (1995):**The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic. Res. 22:375-383.
150. **Rice-Evans, C.A.; Miller, N.J.; Paganga, G. (1997):**Antioxidant properties of phenolic compounds. Trends Plant Sci. 2: 152–159.
151. **Rosén, T.; Bosaeus, I.; Tölle, J.; Lindstedt, G.; Bengtsson, B.A. (1993):**"Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency". Clin. Endocrinol. (Oxf) 38 (1): 63-71.

-
152. **Sabu, M.C.; Smitha, K.; Kuttan, R. (2002):** Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. *J. Ethnopharmacol.* 83: 109–116.
153. **Sai, K.; Kai, S.; Umemura, T.; Tanimura, A.; Hasegawa, R.; Inoue, T.; Kurokawa, Y. (1998):** Protective effects of green tea on hepatotoxicity, oxidative DNA damage and cell proliferation in the rat liver induced by repeated oral administration of 2-nitropropane. *Food Chem. Toxicol.* 36: 1043–1051.
154. **Sakamoto, Y.; Mikuriya, H.; Tayama, K.; Takahashi, H.; et al. (2001):** Goitrogenic effects of green tea extract catechins by dietary administration in rats. *Arch. Toxicol.* 75: 591–596.
155. **Samman, S.; Sandstrom, B.; Toft, M.B.; Bukhave, K.; et al. (2001):** Green tea or rosemary extract added to foods reduces nonheme-iron absorption. *Am. J. Clin. Nutr.* 73: 607–612.
156. **Sanae, F.; Miyaichi, Y.; Kizu, H.; Hayashi, H. (2002):** Effects of catechins on vascular tone in rat thoracic aorta with endothelium. *Life Sci.* 71:2553- 2562
157. **Sarafini, M.; Ghiaelli, A.; Ferro-Luzzi, A. (1996):** In vivo antioxidant effect of green and black tea in man. *Eur. J. Clin. Nutr.* 50: 28–32.
158. **Sarkar, A. and Bhaduri, A. (2001):** Black tea is a powerful chemopreventor of reactive oxygen and nitrogen species: comparison with its individual catechin constituents and green tea. *Biochem. Biophys. Res. Commun.* 284: 173– 178.

-
159. **Satoh, K.; Sakamoto, Y.; Ogata, A.; Nagai, F.; Mikuriya, H.; Numazawa, M.; Yamada, K.; Aoki, N. (2002):**Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats. *Food Chem. Toxicol.* 40: 925–933.
160. **Satterfield, S.; Cutler, J.A.; Langford, H.G.; Applegate, W.B.; Borhani, N.O.; Brittain, E.; Cohen, J.D.; Kuller, L.H.; Lasser, N.L.; Oberman, A. (1991):**Trials of hypertension prevention. Phase I design. *Ann. Epidemiol.* 1(5):455-71.
161. **Sayama, K.; Lin, S.; Zheng, G.; Oguni, I. (2000):** Effects of green tea on growth, food utilization and lipid metabolism in mice. In *Vivo*. 14(4):481-484.
162. **Sazuka, M.; Murakami, S.; Isemura, M.; Satoh, K.; Nukiwa, T. (1995):**Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. *Cancer Lett.* 98: 27–31.
163. **Schemer, (1967):**The blood morphology of laboratory, 3rd ed., P.43. Davis F.A. Company, Philadelphia.
164. **Scott, B.C.; Butler, J.; Halliwell, B.; Aruoma, O.I. (1993):** Evaluation of the antioxidant actions of ferulic acid and catechins. *Free Radic. Res. Commun.* 19: 241–253.
165. **Shamir, R. and Fisher, E.A. (2000):**Dietary therapy for children with hypercholesterolemia. *Am. Fam. Physician.* 61(3):675-682, 685-676.

-
166. **Shen, J.Z.; Zheng, X.F.; Wei, E.Q.; Kwan, C.Y. (2003):** Green tea catechin evoke a phasic contraction in rat aorta via H₂O₂-mediated multiple- signalling pathways. Clin. Exp. Pharmacol. Physiol. 30:88–95.
167. **Shepherd, J. (1994):** Lipoprotein metabolism: an overview. Drugs 47:1–10.
168. **Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R; packard C.J. (1995):** Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301- 1307.
169. **Shixian, Q.; VanCrey, B.; Shi, J.; Kakuda, Y.; Jiang, Y. (2006):**Green tea extract thermogenesis induced weight loss by epigallocatechin-gallate inhibition of catechol-o-methyl transferase. J. Med. Food. 9:451-458.
170. **Siedel, J.H.; Schlumberger, S.; Klose, J.; Washlefeld, A.W. (1991):** J. Clin. Chem. Clin. Bioch. 19:838, quoted from Boehringer Mannheim GMBH Diagnostic Manual.
171. **Skrzydowska, E.; Ostrowska, J.; Farbiszewski, R.; Michalak, K. (2002):**Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine 9: 232–238.
172. **Snow, V.; Barry, P.; Fitterman, N.; Qaseem, A.; Weiss, K. (2005):**"Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians". Ann. Intern. Med. 142 (7): 525-31.

173. **Sohn, O.S.; Surace, A.; Fiala, E.S.; Richie, J.P.; Colosimo, S.; Zang, E.; Weisburger, J.H. (1994):** Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male F344 rat. *Xenobiotica*. 24: 119–127.
174. **SOLVD Investigators (1991):** Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N. Engl. J. Med.* 325:293-302.
175. **SOLVD Investigators (1992):** Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N. Engl. J. Med.* 327:685-691.
176. **Sonne-Holm, S.; Sorensen, T.I.; Jensen, G.; Schnohr, P. (1989):**Independent effects of weight change and attained body weight on prevalence of arterial hypertension in obese and non-obese men. *BMJ*. 299:767.
177. **Stamler, J.; Vaccaro, O.; Neaton, J.D.; Wentworth, D. (1993):**Diabetes other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. *Diabetes Care*. 16: 434-444.
178. **Stanton, J.L.; Braitman, L.E.; Riley, A.M.; Khoo, C.S.; Smith, J.L. (1982):**Demographic, dietary, life style, and anthropometric correlates of blood pressure. *Hypertension*. (5 Pt Su 2):III135-42.
179. **Stensvold, I.; Tverdal, A.; Solvoll, K.; Foss, O.P. (1992):** Tea consumption, relationship to cholesterol, blood pressure, and coronary and total mortality. *Prev. Med.* 21:546-553.

-
180. **Steven, I.D. and Ruth, D. (1993):** Managing hypertension. Aust. Fam. Physician. 22(5):653-5.
181. **Stone, N.J. (1994):** Secondary causes of hyperlipidemia. Med. Clin. North Am. 78(1):117-41
182. **Surh, Y.J.; Chun, K.S.; Cha, H.H.; Han, S.S.; Keum, Y.S.; Park, K.K.; Lee, S.S. (2001):**Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480–481: 243–268.
183. **Tamura, K.; Nakae, D.; Horiguchi, K.; Akai, H.; et al. (1997):**Inhibition by green tea extract of diethylnitrosamine-initiated but not choline-deficient, L-amino acid-defined diet-associated development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in rat liver. Jpn. J. Cancer Res. 88: 356–362.
184. **Tanaka, H.; Hirose, M.; Kawabe, M.; Sano, M.; Takesada, Y.; Hagiwara, A.; Shirai, T. (1997):**Post-initiation inhibitory effects of green tea catechins on 7,12-dimethylbenz[a]anthracene-induced mammary gland carcinogenesis in female Sprague-Dawley rats. Cancer Lett. 116: 47–52.
185. **Tannous, M.; Cheung, R.; Vignini, A.; Mutus, B. (1999):**Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb. Haemost. 82:1390-1394.
186. **Thompson, G.R. (2004):** Management of dyslipidaemia. Heart. 90:949-955.

-
- 187. Tijburg, L.B.; Wiseman, S.A.; Meijer, G.W.; Weststrate, J.A. (1997):** Effects of green tea, black tea and dietary lipophilic antioxidants on LDL oxidizability and atherosclerosis in hypercholesterolaemic rabbits. *Atherosclerosis*. 135: 37–47.
- 188. Turpeinen, O. (1979):** Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. *Circulation*. 59:1-7.
- 189. Ullian, M.E.; Islam, M.M.; Robinson, C.J.; Fitzgibbon, W.R.; Tobin, E.T.; Paul, R.V. (1997):** Resistance to mineralocorticoids in wistar-Furth rats. *Am. J. Physiol.* 272 : 111454 – 111 461.
- 190. Vinson, J.A. and Dabbagh, Y.A. (1998):** Effect of green and black tea supplementation on lipids, lipid oxidation and fibrinogen in hamster: mechanisms for the epidemiological benefits of tea drinking. *FEBS. Lett.* 14;433(1-2):44-46.
- 191. Wakabayashi, K.; Kono, S.; Shinchu, K.; Honjo, S.; Todoroki, I.; et al. (1998):** Habitual coffee consumption and blood pressure: A study of self-defense officials in Japan. *Eur. J. Epidemiol.* 14:669–673.
- 192. Wassertheil, S.; Blaufox; Oberman, A. (1991):** Effect of antihypertensive drugs on sexual function and quality of life: the TAIM study. *Ann. Intern. Med.* 114:613.
- 193. Waszczykowska, E.; Blaszczyk, J.; Sysa-Jedrzejowska, A.; Robak, E. (1997):** Correlation between serum malonyl dialdehyde concentration and disease activity in patients with systemic lupus erythematosus. *Med. Sci. Monit.* 3(6): 831-834.

-
194. **William, B. (1994):**Insulin resistance. *Lancet*. 344:521.
195. **World Health Organization (2000):**Technical report series 894[3], i-253: "Obesity: preventing and managing the global epidemic.", Geneva.
196. **Wu, L.Y.; Juan, C.C.; Ho, L.T.; Hsu, Y.P.; Hwang, L.S. (2004):**Effect of green tea supplementation on insulin sensitivity in Sprague-Dawley rats. *J. Agric. Food Chem.* 52: 643–648.
197. **Xu, Y.; Ho, C.T.; Amin, S.G.; Han, C.; Chung, F.L. (1992):**Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. *Cancer Res.* 52: 3875–3879.
198. **Yamane, T.; Nakatani, H.; Kikuoka, N.; Matsumoto, H.; Iwata, Y.; Kitao, Y.; Oya, K.; Takahashi, T. (1996):** Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. *Cancer.* 77: 1662–1667.
199. **Yamimoto, T.; Juneja, L.R.; Djoing-Chu, C.; Kim, M. (1997):** Chemistry and Applications of Green Tea. Boca Raton, FL: CRC Press: 51-52.
200. **Yang, C.; Chung, J.; Yang, G.; Chhabra, S.; Lee, M. (2000):**Tea and tea polyphenols in cancer prevention. *J. Nutr.* 130:472S–478S.
201. **Yang, C.; Maliakal, P.; Meng, X. (2002):**Inhibition of carcinogenesis by tea. *Annu. Rev. Pharmacol. Toxicol.* 42: 25–54.

-
202. **Yang, J.A.; Choi, J.H.; Rhee, S.J. (1999):** Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats. *J. Nutr. Sci. Vitaminol.* 45: 337–346.
203. **Yang, M.; Wang, C.; Chen, H. (2001):** Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats fed high-sucrose diet. *J. Nutr. Biochem.* 12: 14–20.
204. **Yang, T.T and Koo, M.W. (2000):**Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. *Life Sci.* 66:411-423.
205. **Yang, Y.C.; Lu, F.H.; Wu, J.S.; Wu, C.H.; Chang, C.J. (2004):** The Protective Effect of Habitual Tea Consumption on Hypertension. *Arch. Intern. Med.* 164:1534-1540.
206. **Yokozawa, T.; Nakagawa, T.; Kitani, K. (2002):**Antioxidative activity of green tea polyphenol in cholesterol-fed rats. *J. Agric. Food Chem.* 50: 3549–3552.
207. **Yokozawa, T.; Nakagawa, T.; Lee, K.I.; Cho, E.J.; Terasawa, K.; Takeuchi, S. (1999):** Effects of green tea tannin on cisplatin-induced nephropathy in LLC-PK1 cells and rats. *J. Pharm. Pharmacol.* 51: 1325–1331.
208. **Yu, R., Jiao, J. J., Duh, J. L., Gudehithlu, K., Tan, T. H. & Kong, A. N. (1997):** Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. *Carcinogenesis* 18: 451– 456.

209. **Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; et al. (2004):**"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.". *Lancet*. 364: 937-52.
210. **Zagorsky, J.L. (2004):** Is Obesity as Dangerous to Your Wealth as to Your Health? *Res. Aging*. 26:130-152.
211. **Zeyuan, D.; Bingying, T.; Xiaolin, L.; Jinming, H.; Yifeng, C. (1998):**Effect of green tea and black tea on the metabolisms of mineral elements in old rats. *Biol. Trace Elem. Res*. 65: 75–86.
212. **Zhang, G.; Miura, Y.; Yagasaki, K. (2002):**Effects of dietary powdered green tea and theanine on tumor growth and endogenous hyperlipidemia in hepatoma-bearing rats. *Biosci. Biotechnol. Biochem*. 66:711–716.
213. **Zheng, G.; Sayama, K.; Okubo, T.; Juneja, L.R.; Oguni, I. (2004):**Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. *In Vivo*.18:55–62.
214. **Zusman, R.M. (1993):** Angiotensin-converting enzyme inhibitors: more different than alike? Focus on cardiac performance. *Am. J. Cardiol*. 72 : 25H - 36H.